1 / 53

THE JUDICIOUS USE OF ANTIBIOTICS

THE JUDICIOUS USE OF ANTIBIOTICS. “New medicines, and new methods of cure, always work miracles for a while ” - William Heberden, 1802. INCREASING RESISTANCE IN THE US.

RoyLauris
Download Presentation

THE JUDICIOUS USE OF ANTIBIOTICS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THE JUDICIOUS USE OF ANTIBIOTICS “New medicines, and new methods of cure, always work miracles for a while” - William Heberden, 1802 AIM Infectious Diseases Workshop

  2. INCREASING RESISTANCE IN THE US Thornsberry C. Infect Med. 1993;93 (suppl):15-24. Barry AL. AAC. 1994;38:2419-25. Washington JA. DMID. 1996;25:183-190. Thornsberry C. DMID 1997;29:249-57; Doern GV. AAC. 1996;40:1208-13. Thornsberry C. JAC 1999;44:749-59. AIM Infectious Diseases Workshop

  3. INFECTIOUS DISEASES • Syndrome • Host • Likely pathogens • Antibiotic options AIM Infectious Diseases Workshop

  4. SYNDROME • First distinguish infectious from non-infectious • Allergy • Malignancy • Autoimmune • Drugs AIM Infectious Diseases Workshop

  5. SYNDROMEANATOMY/ORGAN SYSTEM • Site of infection influences • Likely pathogens • ABX activity - penetration, pH, foreign body • Need for ‘cidal’ vs ‘static’ therapy AIM Infectious Diseases Workshop

  6. SYNDROMEANATOMY/ORGAN SYSTEM • General - FUO, adenopathy • Skin/soft tissue - cellulitis, wound infection, necrotizing fasciitis • CNS - meningitis, encephalitis, brain abscess • HEENT - sinusitis, otitis, pharyngitis, abscess • Respiratory - bronchitis, pneumonia • CV - endocarditis, phlebitis, bacteremia, catheter-related AIM Infectious Diseases Workshop

  7. SYNDROMEANATOMY/ORGAN SYSTEM • Abdominal - peritonitis, abscess, cholecystitis/cholangitis, appendicitis • Urinary tract - cystitis, pyelonephritis, perinephric abscess • Genital tract - urethritis, cervicitis, PID, prostatitis • Musculoskeletal - pyomyositis, osteomyelitis, septic arthritis AIM Infectious Diseases Workshop

  8. HOST • Demographics - age, habits • Exposure - sick contacts, residence/travel, hospitalization/institutionalization • Co-morbidities - immunosuppression, organ dysfunction, surgery, foreign bodies • Prior antibiotic use AIM Infectious Diseases Workshop

  9. LIKELY PATHOGENS • Based on syndrome and host AIM Infectious Diseases Workshop

  10. ISOLATION/IDENTIFICATION • Real vs contaminant • Possible presence of others AIM Infectious Diseases Workshop

  11. SUSCEPTIBILITY • Testing may not take into account: • Inoculum effect • ABX concentrations at site of infection • Subpopulations • Repressed but inducible genes AIM Infectious Diseases Workshop

  12. ANTIBIOTIC USAGE PRINCIPLES • Use narrow spectrum when possible • Use older agent when feasible • Use combination therapy only when indicated AIM Infectious Diseases Workshop

  13. ANTIBIOTIC OPTIONS • Staphylococcus aureus • MSSA - antistaphylococcal PCN, 1st or 3rd generation ceph, clindamycin, macrolide, carbapenem • MRSA - vancomycin, linezolid, daptomycin AIM Infectious Diseases Workshop

  14. ANTIBIOTIC OPTIONS • Streptococcus pyogenes • PCN, 1st or 3rd generation ceph, clindamycin, macrolide • Streptococcus pneumoniae • PSSP - PCN, 1st or 3rd generation ceph, clindamycin, macrolide, doxy • PRSP - newer quinolone, 3rd generation ceph, vancomycin AIM Infectious Diseases Workshop

  15. ANTIBIOTIC OPTIONS • Enterococci • PCN-susceptible - PCN/amp ± AGC • PCN-resistant - vancomycin or daptomycin ± AGC • VRE - linezolid, quinopristin/dalfopristin, teicoplanin, daptomycin • AGC-resistant - high-dose continuous infusion PCN/amp AIM Infectious Diseases Workshop

  16. ANTIBIOTIC OPTIONS • Gram-negative rods • Older quinolones, TMP/SMX, 2nd and 3rd generation ceph, beta-lactam/beta-lactamase inhibitor combinations, carbapenem • SPACEY - inducible extended spectrum beta-lactamase production AIM Infectious Diseases Workshop

  17. ANTIBIOTIC OPTIONS • Anaerobes • Metronidazole, clindamycin, beta-lactam/beta-lactamase inhibitor combinations, carbapenem AIM Infectious Diseases Workshop

  18. ABECB • Annual treatment costs in U.S. - inpatient ~$1.6 billion, outpatient ~$40 million (Niederman et al, 1999) • Almost 7 million prescriptions written annually for ABX related to bronchitis = 11% of total ABX prescriptions (Gonzalez et al, 1997) AIM Infectious Diseases Workshop

  19. ABECBCommon Pathogens Fredrick, AM, et al. Clin Ther 2001; 23: 1683-1706. AIM Infectious Diseases Workshop

  20. ABECBTREATMENT STRATEGIES • Simple • Increased dyspnea, sputum, sputum purulence • 1st line: Amox, Doxy, TMP-SMX • Alternatives: Amox-Clav, FQ, macrolide, 2nd generation Ceph • Complicated • Above Sx plus 1 of: frequent exacerbations, co-morbidity, age >65, chronic bronchitis >10 yr • 1st line: FQ • Alternative: Amox-Clav, 2nd-3rd generation Ceph, newer macrolide; consider hospitalization and iv Rx • Chronic • Above plus continuous year-round production of purulent sputum • 1st line: Cipro + Amox-Clav • Alternative: consider hospitalization and iv Rx AIM Infectious Diseases Workshop

  21. OTITIS MEDIACOMMON PATHOGENS AIM Infectious Diseases Workshop

  22. ACUTE OTITIS MEDIADIAGNOSIS • Acute onset • Signs of middle ear effusion • Signs and symptoms of middle-ear inflammation AAP. Pediatrics 2004;113:1451-54. AIM Infectious Diseases Workshop

  23. ACUTE OTITIS MEDIAMANAGEMENT • Pain management • Observation if: • >2 y old • Non-severe illness • Ready means of communication • Able to re-evaluate within 48-72 h if not improved • Ability to obtain medications in timely manner • Antibacterial therapy • Amoxicillin 80-90 mg/kg/d • Alternatives include cephalosporins or newer macrolides • Amoxicillin-clavulanate 90 mg/kg/d for treatment failures AAP. Pediatrics 2004;113:1451-54. AIM Infectious Diseases Workshop

  24. SINUSITISCOMMON PATHOGENS Pfaller et al. AJM 2001; 111: 4S. AIM Infectious Diseases Workshop

  25. SINUSITISDIAGNOSIS • Most important criterion is persistence of nasal purulence for >14 days, associated with daytime cough • Sinus pressure and tenderness are nonspecific markers AIM Infectious Diseases Workshop

  26. SINUSITISTREATMENT Systematic review of 32 trials involving >7000 patients acute maxillary sinusitis => • Penicillin and amoxicillin better than placebo • No significant difference in cure rate between classes of antibiotics for the following comparisons: • Newer non-penicillin antibiotics versus penicillins • Newer non-penicillin antibiotics versus amoxicillin-clavulanate Tang. Ann EM 2003. AIM Infectious Diseases Workshop

  27. PNEUMONIACOMMON PATHOGENS • Streptococcus pneumoniae • Haemophilus influenzae • Moraxella catarrhalis • Legionella pneumophila • Mycoplasma pneumoniae • Chlamydia pneumoniae AIM Infectious Diseases Workshop

  28. PNEUMONIALIKELY PATHOGENS • Alcoholism - S. pneumoniae, anaerobes • COPD and/or smoking - S. pneumoniae, H. influenzae, M. catarrhalis, Legionella species • Poor dental hygiene - anaerobes • Elderly - S. pneumoniae, Legionella spp. • HIV infection (early stage) - S. pneumoniae, H. influenzae, M. tuberculosis, S. aureus, P. aeruginosa • HIV infection (late stage) - above plus P. jerovici (carinii), Cryptococcus, Histoplasma spp. • Corticosteroid therapy - S. pneumoniae, L. pneumophila ,P. aeruginosa AIM Infectious Diseases Workshop

  29. PNEUMONIALIKELY PATHOGENS • Suspected large-volume aspiration - anaerobes (chemical pneumonitis, obstruction) • Structural disease of lung (bronchiectasis, cystic fibrosis, etc.) - P. aeruginosa, Burkholderia cepacia, S. aureus • Injection drug use - S. aureus, anaerobes, M. tuberculosis, S. pneumoniae • Airway obstruction - anaerobes, S. pneumoniae H. influenzae, S. aureus • Recent hospitalization - S. aureus, P. aeruginosa, enteric Gram-negative bacilli AIM Infectious Diseases Workshop

  30. PNEUMONIALIKELY PATHOGENS • Nursing home residency - S. pneumoniae, gram-negative bacilli, H. influenzae, S. aureus, anaerobes, C. pneumoniae • Influenza active in community - influenza, S. pneumoniae, S. aureus, S. pyogenes, H. influenzae • Epidemic legionnaires' disease - Legionella spp. • Exposure to bats or soil enriched with bird droppings - H. capsulatum, C. neoformans • Exposure to birds - Chlamydia psittaci • Exposure to rabbits - Francisella tularensis • Travel to southwestern US - Coccidioides spp. • Exposure to farm animals or parturient cats - Coxiella burnetii (Q fever) AIM Infectious Diseases Workshop

  31. PNEUMONIAMANAGEMENT AIM Infectious Diseases Workshop

  32. UTIDIAGNOSIS • Leukocyte esterase test ~80-90% sensitive, nitrite test ~50% sensitive compared with quantitative culture with greater than or equal to 105 cfu • False-negative nitrite test results may occur with: • low levels of bacteriuria • patients taking diuretics • patients on a low-nitrate diet • infections with bacteria that do not reduce nitrates • Combining both tests improves sensitivity => 85-90% • Specificity ~ 95% for both AIM Infectious Diseases Workshop

  33. UTICOMMON PATHOGENS AIM Infectious Diseases Workshop

  34. UTITREATMENT • Acute uncomplicated cystitis • 3-day treatment with TMP/SMX, FQ • Recurrent cystitis • Treat relapse with 7-day course of FQ, otherwise treat as acute uncomplicated • Acute pyelonephritis • 2-week course AIM Infectious Diseases Workshop

  35. ANTIBIOTIC OVERUSE • Of 6.5 million ABX prescriptions written in 1992 for children younger than 18 (Nyquist AC et al. JAMA 1998;279:875-877.): • 12% for colds • 9% for URI or nasopharyngitis • 9% for bronchitis • In Kentucky study (Mainous AG et al. J Fam Pract 1996;42:357-61): • 60% of patients with common cold received ABXs • Estimated $37.5 million spent for ABX prescriptions in U.S. annually for common cold AIM Infectious Diseases Workshop

  36. AIM Infectious Diseases Workshop

  37. AIM Infectious Diseases Workshop

  38. PATIENT • 43 year old male presents with cough x 3 days AIM Infectious Diseases Workshop

  39. PATIENT AIM Infectious Diseases Workshop

  40. PATIENT AIM Infectious Diseases Workshop

  41. ANTIBIOTIC FAILURE • Persistent or new fever or other signs of infection • Persistent laboratory abnormalities • Development of sepsis or other organ involvement • Persistent isolation of organism from culture AIM Infectious Diseases Workshop

  42. ANTIBIOTIC FAILURE • Antibiotic-related • Compliance • Wrong agent • Wrong dose • Drug interactions • Poor tissue penetration AIM Infectious Diseases Workshop

  43. ANTIBIOTIC FAILURE • Host-related • Immunologic defect • Anatomic defect • Foreign body AIM Infectious Diseases Workshop

  44. ANTIBIOTIC FAILURE • Organism-related • Emergence of resistance • Pre-existing co-infection • Superinfection AIM Infectious Diseases Workshop

  45. AIM Infectious Diseases Workshop

  46. AIM Infectious Diseases Workshop

  47. AIM Infectious Diseases Workshop

  48. AIM Infectious Diseases Workshop

  49. AIM Infectious Diseases Workshop

  50. CONTROLLING OUTPATIENT RESISTANCE • Explain that unnecessary antibiotics may be harmful • Share the facts • Build cooperation and trust • Encourage active management of the illness • Be confident with recommendations to use alternative treatments • Start the educational process in the waiting room (www.cdc.gov/ncidod/dbmd/antibioticresistance) • Involve office personnel in the process AIM Infectious Diseases Workshop

More Related